# Tuyen Ong

> Tuyen Ong is a physician-turned-biotech executive who spent four years as CEO of Ring Therapeutics, the Flagship Pioneering company trying to turn anelloviruses - harmless viruses that already live in nearly everyone - into a redosable delivery system for genetic medicines. Trained as an ophthalmologist at University College London with an MBA from NYU Stern, he built his career on gene therapy for rare eye disease at Nightstar, Biogen, PTC, Bausch & Lomb and Pfizer before betting on a virus most scientists had written off as biological junk. In 2025 he co-founded PharmasMarket, a drug-development consultancy.

- **Role:** Co-Founder & CEO at PharmasMarket; former CEO at Ring Therapeutics
- **Organizations:** PharmasMarket, Ring Therapeutics, Flagship Pioneering, Vyluma, Rectify Pharma, Biogen, Nightstar Therapeutics, PTC Therapeutics, Bausch & Lomb, Pfizer
- **Nationality:** British
- **Education:** MD, University College London, MBA, New York University Stern School of Business, Member (MRCOphth), Royal College of Ophthalmologists
- **Known for:** Led Ring Therapeutics' commensal anellovirus platform (Anellogy) from foundational science to non-human primate data in roughly four years, versus about 15 years historically for AAV, Raised an $86.5M Series C (March 2023) with Flagship, T. Rowe Price, Invus, Kyowa Kirin, UPMC Enterprises and others; company raised ~$253.5M total across rounds, Oversaw preclinical demonstration of redosable viral vectors in primates and durable gene expression sustained over 12 months

## Career timeline

- **pre-2015** — Clinical and drug-development roles at Pfizer, Bausch & Lomb (acquired by Valeant), and PTC Therapeutics across genetics, ophthalmology and rare disease
- **2017-2019** — Chief Development Officer at Nightstar Therapeutics; led gene-therapy clinical and regulatory strategy through its NASDAQ IPO and 2019 acquisition by Biogen
- **2019-2020** — Senior Vice President, Head of Ophthalmology Franchise at Biogen
- **2020-09** — Named CEO of Ring Therapeutics and CEO-Partner at Flagship Pioneering
- **2023-03** — Ring Therapeutics raises $86.5M Series C to advance the Anellogy platform toward the clinic
- **2024** — Ring presents redosable primate retina data and 12-month durable in vivo gene expression for AnelloVector; publishes anellovirus gene-delivery platform
- **2025** — Co-founds PharmasMarket, a pharma and biotech drug-development consultancy

## Achievements

- Led Ring Therapeutics' commensal anellovirus platform (Anellogy) from foundational science to non-human primate data in roughly four years, versus about 15 years historically for AAV
- Raised an $86.5M Series C (March 2023) with Flagship, T. Rowe Price, Invus, Kyowa Kirin, UPMC Enterprises and others; company raised ~$253.5M total across rounds
- Oversaw preclinical demonstration of redosable viral vectors in primates and durable gene expression sustained over 12 months
- As Chief Development Officer at Nightstar Therapeutics, helped take the gene-therapy company public on NASDAQ and through its acquisition by Biogen (2019)
- Over 20 years of clinical and drug-development experience across large pharma and biotech in genetics, ophthalmology and rare disease

## Latest updates

- **2025-09** — Announced a new venture, co-founding PharmasMarket, a pharma/biotech drug-development consultancy
- **2024-10** — Ring presented preclinical data showing expanded AnelloVector payload capacity and durable gene expression over 12 months at ESGCT
- **2024-04** — Ring published its commensal human anellovirus gene-delivery platform
- **2023-03** — Ring Therapeutics closed an $86.5M Series C financing

## Links

- Website: https://ringtx.com
- LinkedIn: http://www.linkedin.com/in/tuyen-ong-6b5642b
- Twitter/X: https://twitter.com/ring_tx
- YouTube: https://www.youtube.com/watch?v=9VCycHuAe9Y

---

Profile page: https://yespress.io/tuyen-ong
Published by YesPress — https://yespress.io
Last updated: 2026-07-07